Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

Tsur N, Kogan Y, Avizov-Khodak E, Vaeth D, Vogler N, Utikal J, et al. Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. J Transl Med. 2019;17(1):338. doi: 10.1186/s12967-019-2081-2. PubMed PMID: 31590677.

READ PUBLICATION
Response of Patients with Melanoma to Immune Checkpoint Blockade - Insights Gleaned from Analysis of a New Mathematical Mechanistic Model

Tsur N, Kogan Y, Rehm M, Agur Z. Response of Patients with Melanoma to Immune Checkpoint Blockade - Insights Gleaned from Analysis of a New Mathematical Mechanistic Model. J Theor Biol. 2019:110033. doi: 10.1016/j.jtbi.2019.110033. PubMed PMID: 31580835

READ PUBLICATION
The tumor burden rise at radiological disease progression associates with poor overall survival in advanced colorectal cancer

Kogan Y, Elishmereni M, Taub E, Agur Z. P-401 The tumor burden rise at radiological disease progression associates with poor overall survival in advanced colorectal cancer. Annals of Oncology (2019) 30(Supplement_4). doi: 10.1093/annonc/mdz183.006.

Link to the Poster

READ PUBLICATION
Predicting imminent disease progression in advanced colorectal cancer by a machine-learning algorithm

Kogan Y, Shannon S, Taub E, Kleiman M, Elishmereni M,  Agur Z.  Predicting imminent disease progression in advanced colorectal cancer by a machine-learning algorithm. J Clin Oncol 37, 2019 (suppl 4; abstr 645)

Link to the Poster

READ PUBLICATION
Increase in tumor burden at disease progression as a predictor of survival in advanced NSCLC patients

Kogan Y, Elishmereni M, Taub E, Agur Z. Increase in tumor burden at disease progression as a predictor of survival in advanced NSCLC patients. J Clin Oncol 36, 2018 (suppl; abstr e21114).

READ PUBLICATION
A new algorithm predicting imminent disease progression in advanced NSCLC patients by machine-learning integration of five serum biomarkers

Kogan Y, Kleiman M, Shannon S, Elishmereni E, Taub E, Aptekar L, Brenner R. M, Berger R, Nechushtan H, Agur Z. A new algorithm predicting imminent disease progression in advanced NSCLC patients by machine-learning integration of five serum biomarkers. J Clin Oncol 36, 2018 (suppl; abstr e21190).

READ PUBLICATION
PrediCare: A new diagnostic tool predicting imminent disease progression in advanced NSCLC patients by machine-learning integration of three serum biomarkers

Y. Kogan, M. Kleiman, S. Shannon, M. Elishmereni, E. Taub, L. Aptekar, R. Brenner, R. Berger, H. Nechushtan, Z. Agur. 176P PrediCare: A new diagnostic tool predicting imminent disease progression in advanced NSCLC patients by machine-learning integration of three serum biomarkers. Journal of Thoracic Oncology , Volume 13 , Issue 4 , S105.

Link to the Poster

READ PUBLICATION
Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data

Elishmereni M, Kheifetz Y, Shukrun I, Bevan GH, Nandy D, McKenzie KM, Kohli M, Agur Z. Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data. Prostate. 2016;76(1):48-57. doi: 10.1002/pros.23099. PubMed PMID: 26419619.

READ PUBLICATION
Complex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein

Kheifetz, Y., Elishmereni, M., Agur, Z. Complex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein. J Pharmacokinet Pharmacodyn 2014 41(5) pp. 479-491., PMID: 25231819.

READ PUBLICATION
Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration

Agur Z, Elishmereni M, Kheifetz Y. Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration. Wiley Interdiscip Rev Syst Biol Med. 2014;6(3):239-53. doi: 10.1002/wsbm.1263. PubMed PMID: 24604755.

READ PUBLICATION
Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.

Vainas O, Ariad S, Amir O, Mermershtain W, Vainstein V, Kleiman M, Inbar O, Ben-Av R, Mukherjee A, Chan S, Agur Z. Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model. Br J Cancer. 2012;107(5):814-22. Epub 2012/07/21. doi: bjc2012316 [pii], 10.1038/bjc.2012.316. PubMed PMID: 22814580; PMCID: 3425973.

READ PUBLICATION
Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization

Jager E., van der Velden V.H., Te Marvelde JG., Walter R.B., Agur Z., Vainstein V. Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. PLoS one 2011 6(9) e24265.

READ PUBLICATION
An integrated disease/pharmacokinetic/pharmacodynamic model suggests improved interleukin-21 regimens validated prospectively for mouse solid cancers

Elishmereni M, Kheifetz Y, Søndergaard H, Viig R. O, Agur Z. An integrated disease/pharmacokinetic/pharmacodynamic model suggests improved interleukin-21 regimens validated prospectively for mouse solid cancers.PLoS Computational Biology 2011 7(9) e1002206.

READ PUBLICATION
From the Evolution of Toxin Resistance to Virtual Clinical Trials – the Role of Mathematical Models in Oncology

Agur Z. From the Evolution of Toxin Resistance to Virtual Clinical Trials – the Role of Mathematical Models in Oncology, Future Oncology, 2010;6(6), (pp. 917-27).

READ PUBLICATION
Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model

Gorelik B., Ziv I., Shohat R., Wick M., Hankins D., Sidransky D., Agur Z. Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res 2008;68(21), (pp. 9033–9040).

READ PUBLICATION
Mathematical modeling as a new approach for improving the efficacy/toxicity profile of drugs: the thrombocytopenia case study

Agur Z., Elishmereni M., Kogan Y., Kheiffetz Y., Ziv I., Shoham M., and Vainstein V. "Mathematical modeling as a new approach for improving the efficacy/toxicity profile of drugs: the thrombocytopenia case study" in 'Preclinical Development Handbook', Shayne Gad Ed., John Wiley & Sons, USA. 2008, pp 1229-1266.

READ PUBLICATION
Optimizing chemotherapy scheduling using local search heuristics

Agur Z., Hassin R., Levy S. Optimizing chemotherapy scheduling using local search heuristics, Operations Research. 2006 Sep;54 (5) 2006 (pp.829-846).

READ PUBLICATION
Biomathematics in the development of personalized medicine in oncology

Agur Z. Biomathematics in the development of personalized medicine in oncology. Future Oncol. 2006 Feb;2 (1):39-42.

READ PUBLICATION
The Cross-Entropy Method for Continuous Multi-Extremal Optimization
Kroese D., P., Porotsky S., Rubinstein R., Y. The Cross-Entropy Method for Continuous Multi-Extremal Optimization. Methodol. Comput. Appl. Probab. Vol. 8 No. 3, 2006 (p.383–407).
READ PUBLICATION
The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model

Vainstein V, Ginosar Y, Shoham M, Ranmar DO, Ianovski A, Agur Z. The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. J Theor Biol. 2005;234(3):311-27. PubMed PMID: 15784267.

READ PUBLICATION